Search results for PX-TA1162

Ocrelizumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1162

Description of Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade General information on Anti-MS4A1/CD20(Homo sapiens) (Ocrelizumab) Monoclonal Antibody Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission.